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Background: Although Bone morphogenetic protein-2 (BMP-2) is a known mediator of bone regeneration and
vascular calcification, to date no study has investigated the relationship between BMP-2 and type 2 diabetes
mellitus (T2DM) and its possible role in coronary artery disease (CAD). The purpose of this study is to evaluate the
relationship of BMP-2 with atherosclerosis and calcification in patients with T2DM.
Methods: 124 subjects were enrolled in this study: 29 patients with T2DM and CAD; 26 patients with T2DM and
without CAD; 36 patients with CAD and without T2DMand 34 without T2DM or CAD (control group). Severity of
coronary lesions was assessed using coronary angiography and intravascular ultrasound (IVUS). Plasma BMP-2 levels
were quantified using a commercially available ELISA kit.
Results: Compared to the control group, the mean plasma BMP-2 level was significantly higher in T2DM patients
with or without CAD (20.1 ± 1.7 or 19.3 ± 1.5 pg/ml, vs 17.2 ± 3.3 pg/ml, P <0.001). In a multivariable linear regression
analysis, both T2DM and CAD were significantly and positively associated with BMP-2 (Estimate, 0.249; standard error
(SE), 0.063; p <0.0001; Estimate, 0.400; SE, 0.06; p <0.0001). Plasma BMP-2 was also strongly correlated with glycosylated
hemoglobin A1c (HbA1c) (Spearman ρ = −0.31; p = 0.0005). SYNTAX score was also significantly associated with BMP-2
(Spearman ρ = 0.46; p = 0.0002). Using the results from IVUS, plasma BMP-2 levels were shown to positively correlate
with plaque burden (Spearman ρ = 0.38, P = 0.002) and plaque calcification (Spearman ρ =0.44, P = 0.0003) and to
negatively correlate with lumen volume (Spearman ρ =0.31, P = 0.01).
Conclusions: Our study demonstrates that patients with T2DM had higher circulating levels of BMP-2 than normal
controls. Plasma BMP-2 levels correlated positively with plaque burden and calcification in patients with T2DM.
Keywords: Bone morphogenetic protein-2, Type 2 diabetes mellitus (T2DM), Coronary artery disease, Plaque burden
and plaque calcificationIntroduction
Bone morphogenetic protein-2 (BMP-2), a member of
the transforming growth factor (TGF) superfamily, plays
a major role in the regulation of conventional and ec-
topic osteogenesis [1,2]. A growing body of evidence
indicates that BMP-2 signaling plays an important
role in vascular disease, including atherosclerosis, plaque
instability [3,4], and vascular calcification and inflamma-
tion [5,6].* Correspondence: zhangming2279@hotmail.com; liujinghua@vip.sina.com
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unless otherwise stated.Specifically, increased levels of BMP-2 exert proin-
flammatory, proatherogenic effects by inducing oxidative
stress and endothelial dysfunction and have been shown
to promote plaque calcification by inducing an osteogenic
phenotype in vascular smooth muscle cells (VSMCs) [7,8]
In the coronary arteries, BMP-2 is regulated by inflamma-
tory stimuli [9] and its upregulation in the vasculature
may also be related to oxidative stress, hyperglycemia and
hyperlipidemia [10,11].
Diabetes mellitus substantially increases the risk of car-
diovascular and peripheral arterial disease [12] and is asso-
ciated with an increased risk of cardiovascular mortality.
People with type 2 diabetes (T2DM) have approximately aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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people without diabetes, even after adjusting for estab-
lished cardiovascular risk factors [13]. The pathophysiology
of vascular disease in diabetes involves abnormalities in
endothelial and VSMCs, and alterations in platelet function
[14,15]. Vascular calcification is also more common in pa-
tients with diabetes and is associated with increased mor-
tality, stroke and amputations [16-19]. Highly prevalent
vascular calcification in patients with T2DM may be re-
lated to biochemical changes [20,21]. For example, Chen
et al. found that high serum glucose levels were associated
with an increased expression of Cbfa1 and BMP-2 and
enhanced the calcification of VSMCs [22,23].
Neverthesless, the role of high glucose concentrations
in atherosclerosis is complex and requires clarification.
In addition, while BMP-2 is a known mediator of vascu-
lar calcification [19], the role of BMP-2 in the develop-
ment of atherosclerosis remains uncertain, particularly
amongst T2DM patients. In this study, we measured
plasma BMP-2 levels in patients with CAD and T2DM
and examined the association between BMP-2 and clini-




Between 6/2/2011 and 6/17/2013, a total of 124 consecu-
tive patients undergoing diagnostic coronary angiography
for the evaluation of coronary artery disease (CAD) were
recruited. The diagnosis of CAD was made using angiog-
raphy and was defined as angiographic evidence of ≥50%
luminal narrowing in at least one segment of a main epi-
cardial coronary artery. Study subjects were divided into
four groups: (i) patients without CAD or T2DM (n = 34);
(ii) patients with T2DM only (n = 26); (iii) patients with
CAD only (n =31) and (iv) patients with T2DM and CAD
(n =29). Diabetes mellitus was diagnosed based upon
the WHO guidelines or current intake of hypoglycemic
agents [24].
Patients with a history of significant concomitant disease
including hepatic failure, renal failure, hepatitis, cardiomy-
opathy, congenital heart disease, bleeding disorders, previ-
ous thoracic irradiation therapy, and malignant diseases
were excluded from the study. This study was approved
by the Beijing Anzhen Hospital Ethics Committee of
Capital Medical University, and informed consent was
obtained from all participants.
Plasma collection and storage
Blood samples were collected in EDTA-containing tubes
(BD, Franklin Lakes, NJ, USA) and plasma was isolated
within 1 hour by centrifugation at 1900 × g for 10 minutes
at 4°C to remove blood cells, and then at 16,000 × g for
10 minutes at 4°C to remove additional cellular nucleicacid attached to cell debris. Plasma samples were stored
at −80°C prior to being analyzed.
Specific BMP-2 ELISA
BMP-2 levels were quantified using a commercially
available ELISA kit (Quantikine, BMP-2 Immunoassay,
R&D Systems, MN USA). All samples were assayed ac-
cording to the manufacturer’s instructions and were
tested in duplicate by personnel blinded to each patient’s
group. The optical density of each well was determined
using a microplate reader at 450 nm. No interference
and no cross-reactivity were expected based on the man-
ufacturer’s instructions.
Coronary angiography and assessment of CAD severity
Coronary angiography was performed according to
standard methods. Each coronary angiogram was scored
by two independent investigators according to the fol-
lowing scores: (1) Vessel score: The number of vessels
with significant (≥50%) stenosis [25]; (2) Synergy between
PCI with Taxus and Cardiac surgery score (SYNTAX
score), an angiographic score that determines the severity
and complexity of disease in coronary lesions of ≥50%
stenosis, in vessels ≥1.5 mm [26-28]. All angiographic var-
iables of the SYNTAX score were computed by two expe-
rienced cardiologists who were blinded to procedural and
clinical data. In cases of disagreement, the final decision
was reached by consensus.
Intravascular ultrasound examination and image analysis
Virtual histology-Intravascular Ultrasound (IVUS) exami-
nations were performed using a 20 MHz, 2.9 F phased-
array IVUS catheter (Eagle Eye Gold, Volcano Corporation,
Rancho Cordova, CA, USA). Vessel and lumen borders
were manually contoured for all frames in each coronary
segment. Quantitative IVUS measurements inclued vessel
volume, lumen volume, plaque volume and percent plaque
burden. Radiofrequency IVUS derived plaque components
were color-coded and reported as the absolute plaque vol-
ume of VH-IVUS parameters [fibrous (dark green), fibro-
fatty (light green), necrotic core (red) and dense calcium
(white)] to assess for plaque composition [29,30]. Simp-
son’s rule for volumetric measurements was used. To com-
pensate for the different segment lengths of each analyzed
artery, all volumetric data were divided by segment length
and displayed as volume index (mm3/mm) [31].
Statistical analysis
Normality of distribution was assessed using Kolmogorov-
Smirnov test. Comparisons between 2 groups were perfor-
med using Fisher’s test, Student’s t test or Mann–Whitney
U test. For comparisons between more than 2 groups,
one-way ANOVA and Tukey-Kramer HSD (honestly sig-
nificant difference) tests were used as appropriate. Pearson
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tive and quantitative variables as appropriate. Correlations
between BMP-2 and other variables were calculated using
Pearson’s correlation coefficient for symmetrically dis-
tributed data and Spearman’s correlation coefficient for
skewed variables. Univariate and multivariable linear re-
gression analyses were performed to identify variables that
were associated with BMP-2 after adjusting for potential
confounders. All tests were two-sided and a p <0.05 was
considered statistically significant. All statistical analyses
were performed using JMP 10 software (SAS Institute,
Inc., Cary, NC, USA).
Results
Baseline clinical characteristics of study participants
Among the 124 subjects, mean age was 59.4 ± 11.7 years
and the proportion of males was 66%. Mean BMP-2 in the
study population was 18.8 ± 2.5 (pg/ml). Of the 124 pa-
tients, 60 were diagnosed as having CAD and 45 patients
had T2DM, and the remainder had neither disease (n = 34).Table 1 Baseline patient characteristics amongst all patients
Clinical variables Normal (n = 34) T2DM (n =
Age, yr 58.0 ± 11 60 ± 2.3
Male Gender, n (%) 21,(61) 20,(77)
Body mass index, kg/m2 26 ± 2.9 27 ± 3.7
Hypertension, n (%) 18(56) 21(84)
Dyslipidemia, n (%) 8(25) 5(21)
Smoking, n (%) 15(76) 12(48)
Blood glucose, mmol/L 5.6 ± 1.1 6.2 ± 2.2
Triglycerides, mmol/L 1.7 ± 1.1 2.0 ± 0.3
Total cholesterol, mmol/L 4.4 ± 0.2 4.3 ± 0.2
Low-density lipoprotein, mmol/L 2.7 ± 0.9 2.7 ± 0.8
High-density lipoprotein, mmol/L 1.0 ± 0.04 1.0 ± 0.04
Hs CRP, mg/L, Median (Q1, Q3) 1.5(0.7,3.7) 0.64(0.4,1.6
Cr, μmol/L Median (Q1, Q3) 72(65,85) 76(67,86)
Ejection fraction, % 64 ± 5.7 63 ± 6.7
LVEDD, mm 47 ± 4.9 50.1 ± 4.5
BMP-2 (pg/mL) 17.1 ± 0.6 19.2 ± 0.3
HbA1c (n %) 5.9 ± 1.52 7.3 ± 1.6
Medications on admission
Aspirin, No. (%) 24(71) 18(69)
Clopidogrel, No. (%) 13(38) 12(46)
Beta-blockers, No. (%) 14(41) 12(48)
ACEI/ARB, No. (%) 14(42) 17(71)
Statins, No. (%) 8(23.5) 15(58)
Insulin, No. (%) 0(0) 17(65)
Oral hypoglycemics, No. (%) 0(0) 18(69)
BMP-2, Bone Morphogenic Protein-2; CAD, Coronary artery disease; HbA1c; Glycosy
ventricular end diastolic diameter; Cr, Serum creatinine; T2DM, Type II Diabetes MelPrevalence of hypertension, dyslipidemia and smoking
was 83 (69%), 86 (71%) and 51 (42%) respectively.
Elevated plasma BMP-2 levels are associated with
the presence of T2DM
BMP-2 levels differed significantly across all groups
(Table 1). Compared to subjects without T2DM or CAD,
mean plasma BMP-2 levels were significantly higher in
patients with T2DM with or without CAD (20.1 ± 1.7 or
19.3 ± 1.5 pg/ml vs 17.1 ± 3.3, P <0.001, respectively)
(Table 1, Figure 1).
Table 2 demonstrates the results of an univariate linear
regression analyses to determine the association between
clinical variables and BMP-2. Random blood glucose
levels, and the presence of T2DM and CAD were signifi-
cantly associated with BMP-2. High-sensitivity C-reactive
protein showed a tendency towards a positive association
with BMP-2 with borderline statistical significance. After
adjustment for traditional cardiovascular risk factors,
random blood glucose, HbA1c, T2DM and CAD were26) CAD (n = 31) T2DM+ CAD (n = 29) P value
57 ± 2.2 61.6 ± 2.0 0.41
21,(68) 20,(61) 0.50




5.5 ± 1.0 7.6 ± 2.8 0.004
2.0 ± 0.2 1.9 ± 0.2 0.63
4.4 ± 0.9 4.2 ± 0.2 0.92
2.7 ± 0.3 2.5 ± 0.9 0.62
1.0 ± 0.03 0.98 ± 0.04 0.80
) 1.2(0.7,2.9) 1.4(0.7,6.5) <0.001
76(66,88) 77(63,84) 0.9
64 ± 7.3 62.2 ± 6.2 0.8
48 ± 5.3 47 ± 4.6 0.20
18.7 ± 0.3 20.1 ± 0.3 P < 0.001








lated hemoglobin A1c; hsCRP, High sensitivity C-reactive protein; LVEDD, Left
litus.
Figure 1 Elevated plasma BMP-2 levels are associated with the presence of DM and CAD. Bars represent average plasma BMP-2 levels amongst
patients in each group. T-bars indicate standard deviation. Groups are as follows: 1; patients without CAD or T2DM, 2; patients with T2DM only; 3,
patients with CAD only and 4, patients with T2DM and CAD. (*p < 0.05 as compared to group without CAD and T2DM; # p < 0.05 as compared to
group with CAD only).
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standard error, 0.16; p =0.04; Estimate, 0.30; standard
error, 0.13; p =0.021; Estimate, 1.565; standard error,
0.434; p =0.0005; Estimate, 1.299; standard error, 0.425;
p =0.0028, respectively) (Table 3). An interaction term
between CAD and T2DM was included in our multivar-
iable analysis and proved not to be significant (p = 0.46)
and so was excluded from our final model. Plasma BMP-2Table 2 Association between BMP-2 with type II diabetes
mellitus and coronary artery disease after adjusting for
traditional cardiovascular risk factors
Variable Estimate Standard error P
Age (Increase by 1 year) 0.57 0.42 0.19
Male gender −0.032 0.07 0.68
Body mass index −0.01 0.009 0.30
Hypertension −0.11 0.08 0.18
Dyslipidemia −0.006 0.08 0.94
Smoking −0.051 0.08 0.50
Random blood glucose, mmol/L
(Increase by 1 mmol/L)
0.12 0.05 0.027
Hs-CRP, mg/L (Increase by 1 mg/L) 0.33 0.19 0.08
HbA1c (n %) (Increase by 1%) 0.17 0.06 0.0079
T2DM −0.39 0.11 0.0002
CAD −0.26 0.09 0.004
Data are expressed as parameter estimates with standard errors. CAD, Coronary
artery disease; HbA1C, glycosylated hemoglobin A1C; Hs-CRP, Highly sensitive
C-reactive protein; T2DM, Type II diabetes mellitus.levels correlated positively with HbA1c (Spearman ρ = 0.31;
p = 0.0005) (Figure 2).
Assessment of CAD severity using coronary angiography
CAD with three-vessel disease was more prevalent in
the CAD and T2DM group compared with the CAD
only group (48.9% vs 20.6%, p = 0.002). When assessing
the severity of CAD using the SYNTAX score, the mean
SYNTAX score in CAD patients with T2DM were sig-
nificantly higher than in patients with CAD only (29.3 +
6.3 vs. 11.7 + 6.2, p < 0.001). Plasma levels of BMP-2 corre-
lated positively with SYNTAX score (Spearman ρ = 0.46;
p = 0.0002) (Figure 3). In a multivariable linear regression
analysis, SYNTAX score was significantly associated
with BMP-2 levels (Estimate, 2.5, standard error, 0.79;
p = 0.0026) (Table 4).Table 3 Association between BMP-2 levels and plaque
volume and dense calcium in patients with coronary
artery disease
Variable Adjusted for traditional risk
Estimate SE P
T2DM 1.565 0.434 0.0005
CAD 1.299 0.425 0.0028
Random blood glucose,
mmol/l (Increase by 1 mmol/l)
0.32 0.160 0.04
HbA1c, % 0.30 0.13 0.021
CAD, Coronary artery disease; HbA1C, glycosylated hemoglobin; T2DM, Type II
diabetes mellitus.
Figure 2 Scatter diagram demonstrating the correlation between BMP-2 levels and HbA1c. HbA1c is significantly positively correlated with plasma
BMP-2 levels.
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intravascular ultrasound
Data derived from IVUS are shown in Table 5. Plaque
volume index and dense calcium were significantly
higher in patients with CAD and T2DM compared to
patients with CAD only (13.9 [12,15] vs. 9.3 [8.2, 12];Figure 3 Scatter diagram demonstrating the correlation between BMP-2 le
with plasma BMP-2 levels.p < 0.0001; 2.7 [2.1, 3.8] vs. 2.0 [1.3, 3.0]; p = 0.023). Lumen
volume index in the CAD and T2DM group was signifi-
cantly lower compared with that in the CAD group (4.4
[3.8, 6.5] vs. 5.8 [4.8, 6.5]; p < 0.001) (Table 5).
In a multivariable linear regression analysis, lumen
volume, plaque volume index and plaque dense calciumvels and SYNTAX score. SYNTAX is significantly positively correlated
Table 4 Virtual Histology-Intravascular Ultrasound parameters amongst study groups
Variable Univariate Adjusted for risk factors
Estimate SE P Estimate SE P
SYNTAX score 2.78 0.76 0.0005 2.5 0.79 0.0026
Lumen volume index, (mm3/mm) −0.34 0.13 0.0126 −0.273 0.13 0.042
Plaque volume index, (mm3/mm) 0.61 0.25 0.018 0.58 0.27 0.035
Dense calcium, (mm3/mm) 0.29 0.09 0.0028 0.31 0.10 0.0025
CAD, Coronary artery disease; SE, Standard error; Data are expressed as parameter estimates with standard errors. Risk factors adjusted for in multivariate analysis:
age, gender, hypertension, hyperlipidemia and smoking.
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standard error, 0.13; p = 0.042 and Estimate, 0.58; standard
error, 0.27; p = 0.035; Estimate, 0.31; standard error, 0.10;
p = 0.0025, respectively) (Table 4).
Plasma BMP-2 levels correlated negatively with lumen
volume index (Spearman ρ = −0.31, P =0.01) (Figure 4A),
and correlated positively with plaque volume index
(Figure 4B), and plaque calcium density (Spearman ρ =0.38,
P =0.002; Spearman ρ =0.44, P =0.0003, respectively)
(Figure 5A). Dense calcium correlated positively with
plasma HbA1c levels. (Spearman ρ =0.29, p = 0.02)
(Figure 5B).
Discussion
In the current study, we examined the association
between plasma BMP-2 levels and CAD in patients with
and without T2DM. Compared to normal subjects,
plasma BMP-2 levels were significantly higher in T2DM
patients with and without CAD. Plasma BMP-2 levels
also correlated positively with random blood glucose
levels and HbA1c. In addition, plasma BMP-2 levels
were significantly higher in patients with CAD compared
to those without CAD and were positively associated
with the severity and extent of coronary lesions. Our
IVUS findings also showed that plasma BMP-2 levels
correlated positively with plaque calcification and plaqueTable 5 Univariate linear regression analysis for plasma level





IVUS vessel length(mm) Median (Q1, Q3) 24 (17,
Lumen volume index, (mm3/mm) Median (Q1, Q3) 5.8 (4.8
Plaque volume index, (mm3/mm) Median (Q1, Q3) 9.3 (8.2
Dense calcium, (mm3/mm), Median (Q1, Q3) 2 (1.3, 3
Fibrotic tissue, (mm3/mm), Median (Q1, Q3) 2.8 (1.8
Necrotic core, (mm3/mm), Median (Q1, Q3) 2.3 (1.5
Fibro-fatty, (mm3/mm) , Median (Q1, Q3) 0.5 (0.1burden, which suggests an important role of BMP-2
in accelerating atherosclerotic progression and plaque
calcification.
BMP-2 is associated with CAD in patients with T2DM
Recent studies have demonstrated that BMP-2 plays an
important role in both physiological and pathological
vascular processes [32,33]. VSMCs represent a significant
source of BMP-2, which has been reported to be highly
expressed in human vessels [34,35]. Moreover, several
studies have consistently shown that BMP-2 enhances
VSMC migration [36,37]. Hyperglycemia plays a key role
in the regulation of the vascular inflammatory response by
activating the recruitment of inflammatory cells to injured
arteries. Hyperglycemia also stimulates atherosclerosis
through various processes including endothelial dysfunc-
tion and cellular proliferation as well as inflammation
[22,38,39]. Although the role of high serum glucose levels
in atherosclerosis is well documented, its role in vascular
calcification is more complex. Our previous study showed
that high glucose levels increased BMP-2 expression, con-
comitantly with NF-kB activation [23]. In the current
study, we extend these findings by showing that plasma
BMP-2 levels correlate positively with HbA1c, suggesting
that chronically elevated glucose levels may enhance BMP-2
expression in patients with T2DM.s of BMP-2





35) 21 (14, 28) 0.22
, 7.4) 4.4 (3.8, 6.5) 0.0051
, 12) 13.9 (12, 15) <0.001
) 2.7 (2.1, 3.8) 0.023
, 4) 3.9 (2.7, 5.9) 0.82
, 3.5) 2.8 (2.2, 4) 0.06
, 0.7) 0.3 (0.1, 0.75) 0.91
Figure 4 Scatter diagram demonstrating the correlation between BMP-2 levels and lumen volume index, and plaque volume index. (A) Plasma BMP-2
is significantly negatively correlated with lumen volume index. (B) Plasma BMP-2 is significantly positively correlated with plaque volume index.
Figure 5 Scatter diagram demonstrating the correlation between BMP-2 levels and plaque dense calcium, and the association between HbA1c
and plaque dense calcium. (A) Plasma BMP-2 is significantly positively correlated with plaque dense calcium. (B) HbA1c is significantly positively
correlated with plaque dense calcium.
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Although BMP-2 is important for bone regeneration and
is a known mediator of vascular calcification, its role in
the regulation of atherosclerotic lesions remains un-
certain. BMP-2 exerts proinflammatory, proatherogenic
effects and can cause oxidative stress in endothelial cells
promoting endothelial cell activation [37]. The current
study demonstrates that plasma levels of BMP-2 are sig-
nificantly higher in patients with CAD. In addition, we
showed that BMP-2 levels are positively associated with
the severity and extent of coronary stenotic lesions as
measured using the SYNTAX score. These results sug-
gest that BMP-2 may play a key role in the pathogenesis
of coronary atherosclerosis.
BMP-2 may be involved in hyperglycemia-induced plaque
calcification
Vascular calcification is commonly found in atheroscler-
osis and is recognized as a marker of plaque burden.
The presence of spotty calcification is associated with
more extensive and diffuse coronary atherosclerosis and
accelerated disease progression despite the use of med-
ical therapy [40]. Arterial stiffness has been shown to be
an independent predictor of cardiovascular mortality
and an early marker of target organ damage by cardio-
vascular disease. Vascular calcification is as a major con-
tributor to loss of arterial compliance [41].
Vascular calcification is common in diabetes and is as-
sociated with high risk of cardiovascular events. Lesion
length, plaque burden, necrotic core, and calcium con-
tent have all been shown to be significantly higher in
nonculprit lesions of diabetic patients [42]. Though it is
known that diabetes is associated with increased vascular
calcification, the pathogenesis is not completely under-
stood. VSMCs are thought to drive the calcification
process [43]. Elevated glucose levels have been shown to
direct osteogenesis by transforming VSMCs and possibly
pericytes into osteoblast-like cells [44]. In vitro studies
have also shown that high-glucose concentrations are as-
sociated with the increased expression of Cbfa1 and
osteocalcin as well as the increased activity of alkaline
phosphatase VSMCs. These changes resulted in en-
hanced calcification and cell proliferation and the in-
creased expression of osteopontin in cultured VSMCs
[22,45] as well as in the medial layers of the carotid
arteries of streptozotocin-induced diabetic rats [46].
Bostrom and Chen et al. also demonstrated that BMP-2
increased calcification and osteogenic differentiation in
calcifying VSMCs, and that exogenous BMP-2 signifi-
cantly increased the calcification in VSMCs [21,47]. In
this study, our IVUS finding showed that plasma BMP-2
levels correlated positively with plaque dense calcium,
which itself correlated positively with plasma HbA1c.
These findings suggests that BMP-2 may have a role inhyperglycemia-induced calcification, though the precise
molecular mechanisms involved require further study.
Limitations
This study was limited by a small sample size that pre-
sented to a University Hospital, likely to constitute a
unique cohort, which may restrict the generalizability of
our results. The cross-sectional design of the study also
makes determining a causal relationship between BMP-2
and CAD challenging. Further prospective studies are re-
quired to determine the role that elevated BMP-2 levels
have on clinical outcomes in patients with CAD.
Conclusion
BMP-2 levels are increased in CAD patients with T2DM
and correlate positively with the extent and complexity
of coronary atherosclerotic disease as well as the degree
of plaque calcification. These finding suggest that BMP-2
may be an important mediator of hyperglycemia-induced
plaque progression and calcification.
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